Olmesartan

SKU: orb1301381

Description

Olmesartan

Research Area

Metabolism Research

Key Properties

• CAS Number: 144689-24-7
• MW: 446.5
• Purity: 99.81%
• Formula: C₂₄H₂₆N₆O₃
• SMILES: C(N1C(C(O)=O)=C(C(C)(C)O)N=C1CCC)C2=CC=C(C=C2)C3=C(C=CC=C3)C=4NN=NN4
• Target: RAAS
• Solubility: DMSO:6.25 mg/mL (14 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:1 mg/mL (2.24 mM)

Bioactivity

• In Vivo:
  The target blood pressure (<130/80 mm Hg) was achieved in nearly 80% of the patients taking olmesartan and 71% taking placebo; blood pressure measured in the clinic was lower by 3.1/1.9 mm Hg in the olmesartan group than in the placebo group. Microalbuminuria developed in 8.2% of the patients in the olmesartan group (178 of 2160 patients who could be evaluated) and 9.8% in the placebo group (210 of 2139); the time to the onset of microalbuminuria was increased by 23% with olmesartan (hazard ratio for onset of microalbuminuria, 0.77; 95% confidence interval, 0.63 to 0.94; P=0.01). The serum creatinine level doubled in 1% of the patients in each group. Slightly fewer patients in the olmesartan group than in the placebo group had nonfatal cardiovascular events--81 of 2232 patients (3.6%) as compared with 91 of 2215 patients (4.1%) (P=0.37)--but a greater number had fatal cardiovascular events--15 patients (0.7%) as compared with 3 patients (0.1%) (P=0.01), a difference that was attributable in part to a higher rate of death from cardiovascular causes in the olmesartan group than in the placebo group among patients with preexisting coronary heart disease (11 of 564 patients [2.0%] vs. 1 of 540 [0.2%], P=0.02).
• Animal Research:
  In a randomized, double-blind, multicenter, controlled trial, Assigned 4447 patients with type 2 diabetes to receive olmesartan (at a dose of 40 mg once daily) or placebo for a median of 3.2 years. Additional antihypertensive drugs (except angiotensin-converting-enzyme inhibitors or ARBs) were used as needed to lower blood pressure to less than 130/80 mm Hg. The primary outcome was the time to the first onset of microalbuminuria. The times to the onset of renal and cardiovascular events were analyzed as secondary end points.

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

inhibit, Olmesartan, Inhibitor, Angiotensin Receptor, angiotensin II receptor, CS 088, CS088, CS-088, RNH6270, RNH-6270, RNH 6270

Compound Identifiers

PubChem CID

158781